Trademarkia Logo

Canada

C$
Trademark Search in Canada
AFFIBODY

View On IC.GC.CA

AFFIBODY
REGISTERED

on 13 Dec 2024

Last Applicant/ Owned by

Affibody AB

Scheeles väg 2SE-171 65 Solna

SE

Serial Number

2114657 filed on 30th Mar 2021

Registration Number

TMA1275652 registered on 13th Dec 2024

Registration expiry Date

30th Mar 2031

Correspondent Address

BORDEN LADNER GERVAIS LLP

World Exchange Plaza100 Queen Street, Suite 1300Ottawa

ONTARIO

CA

K1P1J9

AFFIBODY

Trademark usage description

chemicals used in industry, namely for the manufacture of pharmaceuticals, biopharmaceuticals; biochemical catalysts; chemical reagents namely affinit Read More

Classification Information

Class [001]
Chemicals used in industry, namely for the manufacture of pharmaceuticals, biopharmaceuticals; Biochemical catalysts; Chemical reagents namely affinity reagents for scientific purposes; Chemical reagents namely in vitro diagnostic reagents for scientific purposes; Chemical reagents namely cell culture reagents for laboratory use; Small molecules and biopharmaceutical solutions containing small molecules.

Classification kind code

11

Class [005]
Medical diagnostic reagents and assays; Clinical diagnostic reagents; Diagnostic biomarker reagents for medical purposes; Diagnostic reagents and agents for medical diagnostic use; Diagnostic reagents for clinical laboratory use; Reagents for use in medical genetic testing; Chemicals for use in chromatography (medical, surgical, dental and veterinary); Radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; Pharmaceutical preparations for the treatment of neoplasms; Pharmaceutical preparations for the treatment of cancer diseases; Pharmaceutical preparations for the treatment of inflammatory eye, skin, muscle and joint diseases and disorders; Pharmaceutical preparations for the treatment of diseases and disorders of the immune system; Pharmaceutical preparations for the treatment of autoimmune diseases and disorders; Pharmaceutical preparations for the treatment of local and systemic bacterial infections, viral infections, fungal infections; Pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; Pharmaceutical preparations and substances for the treatment of diseases and disorders of the peripheral nervous system, namely cranial and spinal neuropathies, autonomic neuropathies, sensorimotor neuropathies and plexopathies; Pharmaceutical preparations for the treatment of diseases of the circulatory system; Pharmaceutical preparations for the treatment of diseases of the respiratory system; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical preparations for the treatment of diseases of the blood or blood forming organs; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for the treatment of renal diseases; Pharmaceutical preparations for the treatment of liver diseases; Pharmaceutical preparations for the treatment of disorders of the lymphatic systems namely Lymphangitis, Lymphocytosis, and Mesenteric lymphadenitis; Pharmaceutical preparations for treating and preventing skin and nail diseases; Pharmaceutical preparations for the treatment of metabolic diseases namely obesity, diabetes, metabolic syndrome, inborn errors of metabolism, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of diseases of the digestive system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the treatment of diseases of the endocrine system, namely glucose homeostasis disorders, thyroid disorders, calcium homeostasis disorders and metabolic bone disease, pituitary gland disorders, sex hormone disorders and tumours of the endocrine glands; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for use in ophthalmology; Pharmaceutical preparations for the treatment of diseases of the musculoskeletal system or connective tissue; Pharmaceutical preparations for the treatment of diseases of the genitourinary system, namely prostate, reproductive and urological diseases and disorders.

Classification kind code

11

Class [010]
Contrast media for use in diagnosis and monitoring of disease; Chromatography columns for use in affinity separation; Chromatography media for use in affinity separation; Chromatography media for use in medical research; enzyme-linked immunosorbent assay (ELISA) test kits for medical assay purposes, containing pre-coated plates, detection reagents, buffers, diluents, standards, and substrates; Protein capture reagent on surface plasmon resonance (SPR) sensor chip; Protein capture reagent on microarrays.

Classification kind code

11

Class [042]
Medical research; Scientific research and development in the field of pharmaceuticals and biopharmaceuticals; Pharmaceutical drug development services; Pharmaceutical research and development; Conducting research, development, and evaluations in the field of new pharmaceuticals and biopharmaceuticals; Advising in relation to medical diagnostic services; Medical laboratory services; Medical research laboratory services.

Classification kind code

11

Mark Details

Serial Number

2114657

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 48
on 9th Mar 2023		Agent Changed
Submitted for opposition 22
on 21st Sept 2022		Search Recorded
Submitted for opposition 20
on 21st Sept 2022		Examiner's First Report
Submitted for opposition 223
on 21st Sept 2022		Total Provisional Refusal
Submitted for opposition 256
on 18th Apr 2022		Notification of Possible Opposition Sent
Submitted for opposition 257
on 17th Jun 2021		Designation Notification - Madrid Protocol
Submitted for opposition 31
on 16th Jun 2021		Formalized
Submitted for opposition 1
on 16th Jun 2021		Created
Submitted for opposition 228
on 30th Mar 2021		International Registration
Submitted for opposition 30
on 30th Mar 2021		Filed